Simvastatin, a drug with immune-modulatory effect.

Comparison of effect of Simvastatin ointment and Triamsinolone ointment on improvement of psoriatic plaques in 15 patients with chronic plaque psoriasis in a 4 week period.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013122015334N2

Enrollment

Registered

2014-02-20

Start date

2013-12-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque psoriasis. A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Psoriatic lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region

Interventions

Intervention 1: Control group: 0.05% Triamcinolone ointment will be applied twice a day on one of the lesions till the end of study. Intervention 2: Treatment group: 3% Simvastatin ointment will be ap

Treatment - Drugs

Control group: 0.05% Triamcinolone ointment will be applied twice a day on one of the lesions till the end of study.

Treatment group: 3% Simvastatin ointment will be applied on the symmetric lesion, twice a day till the end of study.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients arriving at dermatology clinic at Faghihi hospital, with age between 18 and 50years; with diagnosis of chronic plaque psoriasis on extensors surfaces of elbow or knee; Each patient must have at least two symmetric lesions; patient must fill out the inform consent form; Patient must have a negative history of treatment for at least 6 months; Patient must not have chronic debilitating disease. Exclusion criteria: If patient develops reaction to the drug; if he/she is unwilling to continue the treatment; If the plaque is infected during or before treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Scaling. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Erythema. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Area. Timepoint: 0, 2nd, 4th week. Method of measurement: The surface area of th lesions will be calculated by two dermatologists by using photos of the lesions. None of the dermatologists know the treatment used for each lesion.	—

Measure

Time frame

Scaling. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Erythema. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Area. Timepoint: 0, 2nd, 4th week. Method of measurement: The surface area of th lesions will be calculated by two dermatologists by using photos of the lesions. None of the dermatologists know the treatment used for each lesion.

—

Secondary

Measure	Time frame
Changes in PASI score. Timepoint: 0, 2nd, 4th week. Method of measurement: According to PASI score by a dermatologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSina Jelodar.

Shiraz University of medical sciences.

Jelodars@sums.ac.ir; sinajelodar@gmail.com+98 71 1624 8576

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026